NIP7

Across TCGA pan-cancer cohorts, NIP7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NIP7 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NIP7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NIP7 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, LSCC, and GBM are the cancer types where NIP7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.515	0.890	<.001	70	view →
LSCC	DFS	Median	II,III,IV	0.853	0.526	.005	33	view →
GBM	OS	Quartile	All	0.605	0.242	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NIP7–CCRCC (DFS)

Open the CCRCC breakdown →